Volume 61, Pages 1-174 (February 2022)

Articles in this issue:

1. Editorial Board 

2. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis 

3. A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer 

4. BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications 

5. A multidisciplinary approach to optimizing care of patients treated with alpelisib 

6. A pre-operative prognostic model predicting all cause and cause specific mortality for women presenting with invasive breast cancer 

7. Adverse health effects after breast cancer up to 14 years after diagnosis 

8. Are English-language online patient education materials related to breast cancer risk assessment understandable, readable, and actionable? 

9. The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up 

10. Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program 

11. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis 

12. Is sarcopenia a missed factor in the management of patients with metastatic breast cancer? 

13. Giving meaning to patient reported outcomes in breast reconstruction after mastectomy – A systematic review of available scores and suggestions for further research 

14. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study 

15. Effect of postmastectomy radiotherapy on pT 1-2N 1 breast cancer patients with different molecular subtypes 

16. Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study 

17. Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China 

18. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer 

19. Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study 

20. Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Associé à la Grossesse) network 

21. The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making